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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is charac-
terized by progressive irreversible airflow obstruction caused
by a mixture of obstructive bronchiolitis and emphysema (1).
COPD is a major health problem worldwide with a high
prevalence and cost. Despite public awareness regarding the
health risks of smoking, mortality from COPD is still ris-
ing (1, 2); therefore, identification of risk factors involved in
COPD is urgently needed to prevent this disease. Although
cigarette smoking is the most important risk factor for the
development of COPD, only a fraction of chronic smokers
develops symptomatic COPD (3), which suggests that genet-
ic factors play an important role in the development of COPD
(4). Based on the known or presumed pathophysiology of
COPD, the genes involved in the recruitment of inflamma-
tory cells, mucociliary clearance, protease-antiprotease imbal-
ance, oxidants-antioxidants imbalance, apoptosis, and xeno-
biotic metabolism have been investigated; however, the results
of such studies have been inconsistent (5). 
A number of genome-wide linkage analyses have identified
chromosomal regions that are likely to contain genes that con-
tribute to the susceptibility to COPD (6-9). For example,
the 2q33.3-2q37.2 region has been found to be associated
with logarithm of the likelihood for linkage scores greater
than 2.0 for the ratio of forced expiratory volume at one sec-
ond (FEV1) to forced vital capacity (FVC) in a study of Boston
Early-Onset COPD families (6). In addition, a similar region
on chromosome 2q was linked to the FEV1/FVC ratio in the
families studied in the Utah Genetic Reference Project (8).
Furthermore, it has been suggested that the 2q33.3-2q37.2
region of linkage contains genes that contribute to COPD
susceptibility through gene-by-smoking interactions (9). 
Using a combination of whole genome-wide linkage anal-
ysis and microarray gene expression analysis of murine and
human lung tissues, DeMeo et al. (10) isolated the SERPINE2
(serine peptidase inhibitor, clade E [nexin, plasminogen acti-
vator inhibitor type 1], member 2) gene, which is located on
chromosome 2q33-35, a genomic region linked to COPD
phenotypes, as a candidate gene for susceptibility to COPD.
In addition, they found a significant association of multiple
single nucleotide polymorphisms (SNPs) in the SERPINE2
gene with COPD-phenotypes in family-based and case-con-
trol studies (10). However, Chappell et al. (11) found no evi-
dence of association of the five SERPINE2 SNPs with COPD
in a European case-control study. Recently, Zhu et al. (12)
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SERPINE2 Polymorphisms and Chronic Obstructive Pulmonary Disease
A number of genome-wide linkage analyses have identified the 2q33.3-2q37.2 region
as most likely to contain the genes that contribute to the susceptibility to chronic
obstructive pulmonary disease (COPD). It was hypothesized that the SERPINE2
gene, which is one of the genes located at the 2q33.3-2q37.2 region, may act as a
low-penetrance susceptibility gene for COPD. To test this hypothesis, the associa-
tion of four SERPINE2 single nucleotide polymorphisms (SNPs; rs16865421A>G,
rs7583463A>C, rs729631C>G, and rs6734100C>G) with the risk of COPD was
investigated in a case-control study of 311 COPD patients and 386 controls. The
SNP rs16865421 was associated with a significantly decreased risk of COPD in a
dominant model for the polymorphic allele (adjusted odds ratio [OR]=0.66, 95% con-
fidence interval [CI]=0.45-0.97, P=0.03). In haplotype analysis, the GACC haplo-
type carrying the polymorphic allele at the rs16865421 was associated with a sig-
nificantly decreased risk of COPD when compared to the AACC haplotype (adjust-
ed OR=0.58, 95% CI=0.38-0.89, P=0.01), and this effect was evident in younger
individuals (adjusted OR=0.30, 95% CI=0.14-0.64, P=0.002). This study suggests
that the SERPINE2 gene contributes to the susceptibility to COPD. 
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examined the association of SERPINE2 SNPs with COPD-
related phenotypes in a Norwegian population and found
that six SNPs were significantly associated with COPD-relat-
ed phenotypes in a family-based association study, and that
five of these SNPs showed replicative associations in a case-
control study. These contradictory results across studies indi-
cate that more genetic association studies in different ethnic
populations are necessary to understand the role of the SER-
PINE2 gene on the COPD susceptibility. Therefore, we con-
ducted a case-control study to evaluate the association of SER-
PINE2 SNPs with the risk of COPD in a Korean population. 
MATERIALS AND METHODS
Study population
The patient group (n=311) consisted of male COPD pati-
ents who visited the respiratory center of Kyungpook Nation-
al University Hospital between July 2006 and December
2006, and the details of the study population have been des-
cribed elsewhere (13). Briefly, COPD was diagnosed accord-
ing to the criteria established by the NHLBI/WHO Global
Initiative for COPD (GOLD) (1). The criteria for COPD were
as follows: chronic respiratory symptoms and signs such as
cough and dyspnea; FEV1/FVC <70% and FEV1 reversibili-
ty after inhaling 200 μ g salbutamol <12% of the pre-bron-
chodilator FEV1. Patients with bronchial asthma were exclud-
ed on the basis of the reversibility of airflow obstruction. In
addition, subjects with radiographic abnormalities sugges-
tive of other significant respiratory diseases such as bronchiec-
tasis and pulmonary tuberculosis were also excluded. The
severity of COPD was classified by the percentage predicted
FEV1, according to the guidelines established by the GOLD:
mild (>80%, GOLD stage I), moderate (50-80%, GOLD
stage II), severe (30-50%, GOLD stage III) or very severe
(<30%, GOLD stage IV). According to the GOLD classifi-
cation, 97 cases (31.2%) had mild disease, 101 cases (32.5%)
were moderate, 86 cases (27.6%) were severe and 27 cases
(8.7%) were very severe. Control subjects (n=386) were select-
ed from a pool of healthy men who visited the general health
check-up center. The enrollment criteria for the controls were
as follows: male, age >45 yr, no known disease and no his-
tory of any disease and no airflow limitation. All of the cases
and controls were ethnic Koreans that resided in Daegu City
or the surrounding regions. A trained interviewer complet-
ed detailed questionnaires for each patient and each control
subject. This study was approved by the institutional review
board of the Kyungpook National University Hospital, and
written informed consent was obtained from each participant.
Genotyping 
We first examined the frequencies of 6 SERPINE2 SNPs
(rs16865421A>G [IVS3-1376], rs6748795G>C [IVS4-1056],
rs7583463A>C [IVS5+360], rs975278A>G [IVS5-209],
rs729631C>G [IVS7+109], and rs6734100C>G [IVS8+
266]), which were found to be significantly associated with
COPD-related phenotypes in a case-control study conducted
by Zhu et al. (12), in 27 healthy Korean individuals by sequ-
encing analysis. The primer sets used for sequencing were
designed based on the GenBank reference sequence (acces-
sion no. NT_005403.16) and the sequence variants were con-
firmed by two independent authors. The SNPs rs6748795
and rs7583463, as well as the SNPs rs975278 and rs729631
were in complete linkage disequilibrium (LD). Therefore,
four SNPs (rs16865421, rs7583463, rs729631, and rs6734100)
were chosen for an association study. The genotypes of the
four SNPs were determined by PCR and melting-curve anal-
ysis using fluorescence-labeled hybridization probes (Light-
Cycler, Roche Diagnostic, Mannheim, Germany). A geno-
type success rate of greater than 96% was achieved using the
LightCycler. Samples that could not be scored by the Light-
Cycler were re-genotyped by direct sequencing using an ABI
PRISM 3700 genetic analyzer (Applied Biosystems, Foster
City, CA, U.S.A.). All genotyping analyses were performed
‘‘blind’’ with respect to the case/control status in order to ensure
quality control. Approximately 10% of the samples were ran-
domly selected to be genotyped again by a different investi-
gator, and the results were 100% concordant. To determine
the analytic accuracy of the melting curve-based genotyping,
10% of the samples were randomly selected using random
number generated from the uniform distribution and then
analyzed by DNA sequencing. The genotypes determined
using the fluorescent hybridization probe melting curve anal-
ysis were 100% concordant with those determined by DNA
sequencing. Information regarding all SNPs, SNP IDs and
allele frequencies was obtained from the NCBI homepage
(http://www.ncbi.nlm.nih. gov/SNP). 
Statistical analysis
The cases and controls were compared using the Student’s
t-test for continuous variables and a chi-suquare test for cate-
gorical variables. Each of the SNPs was analyzed for Hardy-
Weinberg equilibrium using the goodness-of-fit test, as im-
plemented through SAS Genetics, version 9.1.3 (SAS insti-
tute, Gary, NC, U.S.A.). The LD structure among SNPs was
examined using HaploView 4.0 (14), which is available at
http://www. broad.mit.edu/mpg/haploview. LD blocks were
inferred from the definition proposed by Gabriel et al. (15).
Haplotype frequencies were estimated based on a Bayesian
algorithm using PHASE 2.1 (16). Unconditional logistic
regression analyses were used to calculate the odds ratio (OR)
and 95% confidence interval (CI), with adjustment for pos-
sible confounders (age and pack-years of smoking as contin-
uous variables). In addition to the overall association analy-
sis, we performed a stratified analysis according to age, smok-SERPINE2 Polymorphisms and COPD 1121
ing status and severity of COPD to further explore the asso-
ciation between genotypes/haplotypes and the risk of COPD
in each stratum. To correct for multiple testing, we applied
the Bonferroni correction based on the effective number of
independent SNPs (Meff) for genotype analysis and the Ben-
jamini and Hochberg’s method for haplotype analysis (17,
18). To assess the potential interaction between genotype/
haplotype and smoking (smoking status or pack-years of smok-
ing), we first included the interaction term in the logistic
model. The interaction between genotype/haplotype and
smoking was not statistically significant, and was therefore
removed from the model. All of the analyses were performed
using Statistical Analysis Software for Windows, version 9.1.3
(SAS institute).
RESULTS
The baseline characteristics of the cases and controls enrolled
in this study are shown in Table 1. The FEV1 and FEV1/FVC
ratio were significantly lower in the COPD group than in
the control group. 
The genotype and polymorphic allele frequencies of the
four SERPINE2 SNPs (rs16865421A>G, rs7583463A>C,
rs729631C>G, and rs6734100C>G) in the cases and controls
are shown in Table 2. The genotype distributions of the four
SNPs in the controls were in Hardy-Weinberg equilibrium.
The frequency of the rs16865421G allele was a borderline
significantly lower in the cases than in the control (P=0.06),
and the presence of at least one rs16865421G allele was asso-
*t-test; 
� χ 2 test; 
� Numbers in parenthesis, column percentage; 
�In current
and former smokers.
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
Variables COPD (n=311) Control (n=386) P
Age (yr) 65.5±8.1 60.4±8.0 <0.001*
Smoking status <0.001
�
Current 171 (55.0)
� 205 (53.1)
Former  129 (41.5) 128 (33.2)
Never 11 (3.5) 53 (13.7)
Pack-years
� 42.6±20.0 30.8±16.9 <0.001*
FEV1 (% predicted) 63.4±26.3 104.9±16.8 <0.001*
FEV1/FVC (%) 49.7±13.1 80.7±7.4 <0.001*
Table 1. Characteristics of the study population
All (n=311/386)
Case No./
Control No.*
Polymor-
phism/
Genotype OR (95% CI)
� P
� P
�
Age ≤60 yr (n=83/203)
Case No./
Control No.*
OR (95% CI)
� P
� P
�
Age >60 yr (n=288/183)
Case No./
Control No.*
OR (95% CI)
� P
� P
�
rs16865421A>G (IVS3-1376)
AA        242/275 0.14 1.00 70/144 0.06 1.00 172/131 0.51 1.00
AG 64/103 0.64 (0.43-0.95) 0.03 12/53 0.45 (0.22-0.92) 0.03 52/50 0.79 (0.49-1.27) 0.33
GG 5/8 0.92 (0.26-3.26) 0.90 1/6 0.46 (0.05-3.93) 0.48 4/2 1.33 (0.22-7.97) 0.75
G carriers 69/111 0.048 0.66 (0.45-0.97) 0.03 13/59 0.02 0.45 (0.23-0.89) 0.02 56/52 0.38 0.81 (0.51-1.30) 0.38
MAF
‖ 0.12/0.15 0.06 0.08/0.16 0.02 0.13/0.15 0.51
rs7583463A>C (IVS5+360)
AA 165/221 0.35 1.00 39/115 0.31 1.00 126/106 0.51 1.00
AC 123/145  1.17 (0.83-1.65) 0.37 37/76  1.42 (0.82-2.46) 0.21 86/69  1.00 (0.64-1.55) 0.99
CC 23/20  1.91 (0.97-3.78) 0.06 7/12  1.50 (0.53-4.26) 0.45 16/8  2.31 (0.91-5.85) 0.08
MAF 0.27/0.24 0.17 0.31/0.25 0.13 0.26/0.23 0.38
rs729631C>G (IVS7+109)
CC 87/122 0.58 1.00 21/63 0.58 1.00 66/59 0.70 1.00
CG 154/183  1.27 (0.87-1.87) 0.22 43/101 1.34 (0.71-2.51) 0.37 111/82  1.20 (0.74-1.95) 0.45
GG    70/81  1.24 (0.78-1.97) 0.36 19/39   1.35 (0.63-2.90) 0.44 51/42  1.08 (0.61-1.92) 0.78
MAF   0.47/0.45 0.34 0.49/0.44 0.30 0.47/0.45 0.70
rs6734100C>G (IVS8+266)
CC 201/238  0.56 1.00 59/124  0.26 1.00 142/114  0.91 1.00
CG 101/132  0.94 (0.66-1.33) 0.71 22/70 0.68 (0.38-1.22) 0.20 79/62  1.11 (0.72-1.73) 0.64
GG 9/16  0.61 (0.25-1.52) 0.29 2/9 0.44 (0.09-2.17) 0.31 7/7 0.75 (0.24-2.31) 0.61
MAF 0.19/0.21 0.33 0.16/0.22 0.10 0.20/0.21 0.90
Table 2. SERPINE2 genotypes of COPD cases and controls, and their association with the risk of COPD
*Number of cases/number of controls; 
� Two-sided χ
2 test for either genotype distributions or allele frequencies between cases and controls; 
� Odds ratios
(ORs), 95% confidence intervals (95% CIs) and P values were calculated by unconditional logistic regression analysis, adjusted for age and pack-years
of smoking; 
�ORs (95% CIs) and P values were calculated by unconditional logistic regression analysis, adjusted for pack-years of smoking; 
‖Minor allele
frequency.
Threshold P value for a significant association=0.014, based on Bonferroni correction for the effective number of independent tests (Meff=3.59). 1122 S.I. Cha, H.-G. Kang, J.E. Choi, et al.
ciated with a significantly decreased risk of COPD when com-
pared to the homozygous wild-type genotype (adjusted OR=
0.66, 95% CI=0.45-0.97, P=0.03, corrected P [Pc] for mul-
tiple testing by Meff=0.11). When the subjects were strati-
fied by median age (≤60 yr/>60 yr), the presence of at least
one rs16865421G allele was associated with a significantly
decreased risk of COPD when compared to the AA geno-
type in the younger-aged group (adjusted OR=0.45, 95%
CI=0.23-0.89, P=0.02, Pc=0.08), but not in older individ-
uals (adjusted OR=0.83, 95% CI=0.51-1.30, P=0.38). The
genotype and allele frequencies of the other three SNPs exam-
ined were not significantly different between the cases and
controls. 
We next examined the association between the haplotypes
of the four SERPINE2 SNPs and the risk of COPD. The four
SERPINE2 SNPs were in strong LD (|D’| value: range from
0.90 to 1.00; Fig. 1). Among the 10 haplotypes observed,
five had a frequency of less than 1% and were excluded from
the analysis. The remaining five haplotypes accounted for
98.0% of the chromosomes obtained from the 697 subjects
(cases: 98.2% and controls: 97.8%). Consistent with the results
of the genotyping analysis, haplotype 5 (ht5, rs16865421G/
rs7583463A/rs729631C/rs6734100C), carrying the rs168-
65421G allele, was associated with a significantly decreased
risk of COPD when compared to the ht1 (rs16865421A/
rs7583463A/rs729631C/rs6734100C; adjusted OR=0.58,
95% CI=0.38-0.89, P=0.01, Pc for multiple testing by Hoch-
berg and Benjamini’s method=0.04, Table 3). When the sub-
jects were stratified by median age, the distribution of the
inferred haplotypes of the cases was significantly different
All
Controls
(n=758)
�
Cases
(n=608)
�
Adjusted OR
�
(95% CI)
P
�
Age ≤60 yr
Controls
(n=398)
�
Cases
(n=160)
�
Adjusted OR
�
(95% CI)
P
�
Age >60 yr
Controls
(n=360)
�
Cases
(n=448)
�
Adjusted OR
�
(95% CI)
P
�
ht1, 1111 153 (20.2)  141 (23.2) 1.00 79 (19.9) 47 (29.4) 1.00 74 (20.6)  94 (21.0) 1.00
ht2, 1112  160 (21.1) 115 (18.9) 0.75  0.12 85 (21.4) 25 (15.6) 0.47  0.01
‖ 75 (20.8)  90 (20.1) 1.02  0.93
(0.52-1.08) (0.26-0.85) (0.64-1.63)
ht3, 1121 153 (20.2)  122 (20.1) 0.77  0.16 76 (18.8) 29 (18.1) 0.60  0.08 78 (21.7)  93 (20.8) 0.93  0.77
(0.54-1.11) (0.34-1.06) (0.59-1.48)
ht4, 1221  182 (24.0)  164 (27.0) 1.00  1.00 99 (24.9) 48 (30.0) 0.77  0.32 83 (23.1)  116 (25.9) 1.22  0.38
(0.71-1.41) (0.46-1.29) (0.78-1.92)
ht5, 2111 110 (14.5)  66 (10.9) 0.58  0.01
‖ 60 (15.1)  11 (6.9) 0.30  0.002
¶ 50 (13.9)  55 (12.3) 0.83  0.49
(0.38-0.89) (0.14-0.64) (0.49-1.41)
Global P 0.14 0.008 0.88
Table 3. Distribution of the SERPINE2 haplotypes in the cases and controls
*Wild-type allele is denoted by 1 and polymorphic allele, by 2. The order of the polymorphisms is as follows; rs16865421A>G, rs7583463A>C,
rs729631C>G and rs6734100C>G; 
� Five haplotypes that had a frequency of less than 1% were excluded from analysis; controls, 14 (age ≤60, 8; and
age >60, 6) and cases, 14 (age ≤ 60, 6; and age >60, 8); 
� OR (95% CI) and corresponding P values were calculated by unconditional logistic regres-
sion analysis, adjusted for age and pack-years of smoking; 
�OR (95% CI) and corresponding P values were calculated by unconditional logistic
regression analysis, adjusted for pack-years of smoking. Corrected P value (Pc) by Hochberg and Benjamini’s method; 
‖Pc=0.04 and 
¶Pc=0.02.
Haplotype*
Fig. 1. Linkage disequilibrium (LD) blocks
between SERPINE2 polymorphisms in 27
healthy Koreans (A) and the subjects (n=697)
of a case-control study (B). The LD blocks
were generated by the Haploview program.
Black boxes indicate complete LD (|D’|=1.0
and r
2=1.0). Dark gray boxes indicate strong
evidence of LD (confidence interval [CI] min-
ima for strong LD: upper 0.98, low 0.7; frac-
tion of strong LD in informative comparisons
must be at least 0.95). White boxes indicate
strong recombination (upper CI ≤0.9), and
the gray boxes indicate uninformative find-
ings. Triangles indicate haplotype blocks.
Numbers in squares are |D’| (×100) values.
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from that of the controls in the younger age group (Pdf=5=
0.008), but not in the older age group. Haplotype 5 was asso-
ciated with a significantly decreased risk of COPD when com-
pared to the ht1 in the younger individuals (adjusted OR=
0.30, 95% CI=0.14-0.64, P=0.002, Pc=0.02), but not in the
older individuals (adjusted OR=0.83, 95% CI=0.49-1.41,
P=0.49).
The association of the SERPINE2 SNPs and haplotypes
were further examined after stratifying the subjects according
to smoking status, smoking exposure level, and quantitative
(FEV1 and FEV1/FVC) and qualitative (severity of COPD)
spirometric phenotypes of COPD. There were no effect mod-
ification by smoking status and smoking exposure level. In
addition, the SNPs and haplotypes were not significantly
associated with the quantitative and qualitative spirometric
phenotypes of COPD (data not shown). 
DISCUSSION
We investigated the association between SNPs in the SER-
PINE2 gene, which is a positional candidate gene for COPD
susceptibility, and the risk of COPD in a Korean population.
In the present study, the SNP rs16865421 and haplotypes
composed of the four SNPs rs16865421, rs7583463, rs729631,
and rs6734100, were significantly associated with the risk
of COPD, particularly in younger individuals. This study is
an important addition to previous studies that have shown
an association between SERPINE2 SNPs and COPD-related
phenotypes. In addition, this is the first case-control study
investigating an association of SERPINE2 SNPs with the
risk of COPD in an Asian population. 
In the present study, the polymorphic allele frequencies of
the SERPINE2 SNPs rs16865421A>G, rs7583463A>C,
rs729631C>G, and rs6734100C>G among healthy Koreans
were 0.15, 0.24, 0.45, and 0.21, respectively, which were simi-
lar to those of Asians quoted in the NCBI database. However,
the frequencies were significantly different from those of Nor-
wegians (0.08, 0.82, 0.84, and 0.13 respectively) (12), Euro-
peans (0.04, 0.83, 0.16, and 0.13, respectively) and Africans
(0.17, 0.59, 0.32, and 0.03, respectively) reported in the NCBI
database. 
To date, three studies investigating the association of SER-
PINE2 SNPs and COPD-related phenotypes have been re-
ported; however, the results have been inconsistent. DeMeo
et al. (10) evaluated the associations of 48 SERPINE2 SNPs
with COPD phenotypes in both family and case-control co-
horts, and found that 18 SNPs were significantly associated
with quantitative and/or qualitative spirometric phenotypes
in the family study of severe early-onset COPD pedigrees,
and that eight SNPs (rs1438831, rs7579646, rs840088,
rs7562213, rs920251, rs3795877, rs6747096, and rs3795879),
including 5 SNPs (underlined), that were significant in the
family-based study demonstrated a significant association with
severe COPD (FEV1 of ≤45% predicted) in a case-control
study of American Caucasians. In contrast, Chappell et al. (11)
reported that five SNPs (rs1438831, rs920251, rs6747096,
rs3795879, ss49785625) that were significantly associated
with COPD phenotypes in the family-based or case-control
study conducted by DeMeo et al. (10) were not significantly
associated with the risk of COPD in a European case-control
study. Furthermore, Zhu et al. (12) investigated the associa-
tion of 25SERPINE2 SNPs with COPD phenotypes in a fam-
ily-based study and a case-control study in a Norwegian pop-
ulation. They reported that five SNPs (rs6748795, rs7583463,
rs975278, rs729631, and rs6734100) were significantly asso-
ciated with the risk of COPD in the family-based study. How-
ever, in the case-control study, only the SNP rs16865421 was
associated with a significantly increased risk of COPD, while
the five SNPs (rs6748795, rs7583463, rs975278, rs729631,
and rs6734100) were only associated with a reduction of FEV1
and/or FEV1/VC in the COPD patients. In the current study,
we examined the six SERPINE2 SNPs that were significantly
associated with COPD-related phenotypes in the study con-
ducted by Zhu et al. (12). In concordance with their study,
we found that the SNP rs16865421 was significantly asso-
ciated with the risk of COPD in the present case-control study
performed in a Korean population; however, the other five
SNPs were not associated with the quantitative spirometric
phenotypes. In addition, in contrast to the Norwegian study
(12), the SNP rs16865421 was found to be associated with
a significantly decreased risk of COPD in this study.
Although it is hard to decipher the reasons for the different
results across studies, particularly the conflicting association
of the SNP rs16865421 with COPD, the different genetic
backgrounds and environmental factors in the study popu-
lations may have been responsible for these differences. The
allele and genotype frequencies of the SERPINE2 SNPs, as
well as the status of LD between the SNPs, vary greatly bet-
ween ethnic groups (10-12, 19). Therefore, the genetic effects
of the SERPINE2 SNPs and haplotypes on the susceptibility
to COPD may differ by ethnicity. In a complex polygenic
disease such as COPD, it is likely that multiple genes are
involved in its pathogenesis, which would result in the genet-
ic susceptibility being dependent on the coincidence of sev-
eral polymorphisms acting together. Therefore, a protective
genotype in one population may increase the risk of COPD
in another population due to other linked polymorphisms
that exhibit stronger effects on the susceptibility to COPD.
These discrepancies may be related to differences in the dis-
tribution of COPD phenotypes across studies. COPD is a het-
erogeneous disorder that includes obstructive bronchiolitis
and emphysema. These COPD phenotypes share some sim-
ilar pathophysiology, and likely share some similar genetic
determinants; however, there may also be divergent underly-
ing pathways involved in their development (20, 21). There-
fore, it is possible that the effects of the SERPINE2 SNPs
on the risk of COPD will differ according to the phenotype1124 S.I. Cha, H.-G. Kang, J.E. Choi, et al.
of COPD (19-21). In addition, differences in the severity of
the disease in COPD cases across different studies should be
also considered. Furthermore, the SERPINE2 SNPs and hap-
lotypes were only associated with the risk of COPD in younger
individuals in the present study. This may indicate that the
negative association observed in the study conducted by Chap-
pell et al. (11) occurred due to their study primarily consist-
ing of older-aged patients. The inadequacies in the study
design, such as nonrandom sampling, limited sample sizes
and the pitfalls arising from unknown confounders, also need
be considered. 
The physiologic function of SERPINE2 and its role in the
pathogenesis of COPD remains to be elucidated. One of the
most prevailing hypotheses for the pathogenesis of COPD is
the inflammatory theory, which suggests that cigarette smoke
and other inhaled irritants stimulates inflammatory cells such
as neutrophils, macrophages and CD8+ T cells to release a
variety of mediators, oxidants and proteases. These inflam-
matory events then induce airways remodeling and parenchy-
mal destruction. Based on this theory, disturbance of the bal-
ance between proteases and their inhibitors by an excess of
protease or lack of inhibitor is believed to allow structural
damage to the lung to occur (22, 23). SERPINE2 is a 43-
kDa member of the serine protease inhibitor (SERPIN) super-
family that has been shown to inhibit several serine proteas-
es, including thrombin, urokinase, and plasmin, which play
important roles in inflammation and wound repair following
tissue injury (24, 25). In addition, it has been shown that
SERPINE2 gene expression is up-regulated by cytokines such
as interleukin-1, tumor necrosis factor-α , and transforming
growth factor-β , which play important roles in the develop-
ment of COPD (26, 27). Taken together, these findings sug-
gest that SERPINE2 may play a role in the pathogenesis of
COPD by mediating the maintenance of the protease-antipro-
tease balance (10, 12). However, further studies must be con-
ducted to confirm this.
In disease-gene association studies, analysis of haplotypes
composed of multiple SNPs can increase the power to detect
disease associations when compared with single SNP analy-
sis due to the higher heterozygosity and tighter LD with the
disease-causative variants. In addition, these analyses allow
for the possibility of an ungenotyped functional variant to
be in LD with the genotyped SNPs (28, 29). Because none
of the SERPINE2 SNPs examined in the present study were
located in potentially functional regions of the gene, it is like-
ly that the association between the SNPs and COPD suscep-
tibility may be due to LD with other functional SERPINE2
variant(s) rather than to direct functional effects of the SNPs
examined. Therefore, our investigation was extended to an
analysis of the SERPINE2 haplotypes composed of the four
SNPs. In the haplotype analysis, ht5 was associated with a
significantly decreased risk of COPD when compared to ht1
among the four haplotypes carrying the rs16865421A allele. 
It is important to note that this study had several limita-
tions. Because this study was designed to evaluate the effects
of SERPINE2 SNPs on the risk of overall COPD, the strati-
fication analyses according to age, smoking status and spiro-
metric phenotypes might have a type I error (due to multi-
ple comparisons) and/or a type II error (due to the small num-
ber of subjects in the subgroups). Therefore, additional stud-
ies with a larger sample sizes should be conducted to confirm
our findings. Second, among several candidate SNPs in the
SERPINE2 gene, only 6 intronic SNPs were examined, which
obviously limit the ability to elucidate the entire effect of the
SERPINE2 gene on the susceptibility to COPD. Therefore,
a comprehensive evaluation of SERPINE2 SNPs and identi-
fication of functional variants are needed to better understand
the role of SERPINE2 in the development of COPD.
In conclusion, this case-control study demonstrates a sig-
nificant association of SERPINE2 SNPs and haplotypes with
decreased risk of COPD, particularly among younger indi-
viduals. However, because this is the first case-control study
investigating the associations of SERPINE2 SNPs with the
risk of COPD in an Asian population, additional studies are
required to confirm our findings. Moreover, further study is
needed to identify functional variants of the SERPINE2 gene.
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